BIOAFFINITY TECHNOLOGIES INC
BIAFNASDAQ🏆 #5080 by market capUS Equity
$2.92▼ $0.06 (−2.01%)
Market closed · at closeTrack BIAF
Get earnings, price moves & breaking news on Telegram
24h▼ 2.0%
7d▼ 19.1%
14d▼ 27.0%
30d▼ 56.9%
ytd▼ 84.3%
1y▼ 92.1%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
-23.2%
Declining
📊Gross Margin
34.6%
Moderate
💵FCF Margin
—
⚖️P/S Ratio
0.6x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.92 – $2.92
- 52-Week Range
- $2.66 – $80.70
- Volume (shares)
- 518
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.3M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-6.89
- Dividend Yield
- —
- Dilution (1yr)
- +316.7%
BIOAFFINITY TECHNOLOGIES INC
BIAFFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▼ −34.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
23.2%▼ −35.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▲ +18.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +27.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
115K▲ +316.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$6M YoY
StockOtter · stockotter.spaceAbout BIOAFFINITY TECHNOLOGIES INC
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.